Please login to the form below

Not currently logged in
Email:
Password:

NICE appoints Andy McKeon to Board

The National Institute for Health and Clinical Excellence has appointed Andy McKeon as a non-executive member of its Board

The National Institute for Health and Clinical Excellence (NICE) has appointed Andy McKeon as a non-executive member of its Board.

McKeon, who is managing director of health at the Audit Commission, will replace Mark Taylor who stepped down in April to take up the role of chair at an NHS Mental Health Trust.

Before joining the Audit Commission, McKeon was director of policy and planning at the Department of Health (DH) with responsibility for setting targets for the reform and improvement of health and social care policy agenda. During his time in post he was responsible for all aspects of the clinical and cost effective use of medicines in the NHS.

Mercy Jeyasingham, MBE, has been reappointed to her non-executive role on NICE's board for a further two-year term. A former member of the Ministerial Advisory Board for the Medicines Control Agency, Mercy is a management consultant and trainer who has held significant senior roles in both the public and voluntary sectors.

The appointments were made by the independent organisation the Appointments Commission which is responsible for appointing chairs and non-executive directors to NHS organisations on behalf of the Secretary of State for Health.

 

25th June 2009

From: Healthcare

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics